Q

Quoin Pharmaceuticals Ltd
NASDAQ:QNRX

Watchlist Manager
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Watchlist
Price: 0.585 USD -5.65% Market Closed
Market Cap: 3m USD
Have any thoughts about
Quoin Pharmaceuticals Ltd?
Write Note

Quoin Pharmaceuticals Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Quoin Pharmaceuticals Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Q
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Compugen Ltd
NASDAQ:CGEN
Revenue
$59.9m
CAGR 3-Years
96%
CAGR 5-Years
N/A
CAGR 10-Years
23%
B
Biolight Life Sciences Ltd
TASE:BOLT
Revenue
â‚Ş198k
CAGR 3-Years
63%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
No Stocks Found

Quoin Pharmaceuticals Ltd
Glance View

Market Cap
3m USD
Industry
Life Sciences Tools & Services

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

QNRX Intrinsic Value
2.695 USD
Undervaluation 78%
Intrinsic Value
Price
Q

See Also

What is Quoin Pharmaceuticals Ltd's Revenue?
Revenue
0 USD

Based on the financial report for Jun 30, 2024, Quoin Pharmaceuticals Ltd's Revenue amounts to 0 USD.

Back to Top